January 2019 in “Egyptian Journal of Dermatology and Venereology /Egyptian Journal of Dermatology and Venerology” Mixing calcipotriol with a steroid is almost as effective as using a steroid alone for alopecia areata and has fewer side effects.
August 2018 in “Journal of the American Academy of Dermatology” Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.
April 2018 in “Journal of Investigative Dermatology” Both Th1 and Th2 immune responses are increased in alopecia areata, with Th2 response more strongly linked to how severe the disease is.
January 2018 in “Journal of the American Academy of Dermatology” Combining pulsed prednisone with tofacitinib can lead to lasting hair regrowth in severe alopecia areata patients.
June 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
April 2017 in “Leukemia research” Tofacitinib helped most teenagers in the study regrow hair with mild side effects.
February 2011 in “Annales de dermatologie et de vénéréologie” Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.
October 2024 in “Asian Journal of Pharmaceutical and Clinical Research” Topical methotrexate is more effective and as safe as betamethasone for treating alopecia areata.
March 2026 in “The American Journal of Managed Care” JAK inhibitors can help treat alopecia areata but have risks and high costs.
JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.
November 2025 in “Journal of Investigative Dermatology” IMG-007 helps regrow hair and reduce scalp inflammation in severe alopecia areata.
October 2025 in “Archives of Dermatological Research” Topical metformin gel is as effective and safe as steroids for treating alopecia areata.
Children with alopecia areata have lower BDNF levels, linked to worse symptoms and quality of life.
July 2025 in “Journal of Cosmetic Dermatology” Triamcinolone is more effective than methotrexate for treating localized alopecia areata.
July 2025 in “Journal of Investigative Dermatology” Switching Janus kinase inhibitors helped some patients with severe alopecia areata regrow hair, but insurance issues can worsen the condition.
July 2025 in “International Journal of Trichology” Intralesional methotrexate and triamcinolone acetonide are more effective than Vitamin D3 for treating alopecia areata.
July 2025 in “International Journal of Dermatology Venereology and Leprosy Sciences” Higher stress levels may worsen alopecia areata, suggesting stress management is important for treatment.
June 2025 in “Preprints.org” Baricitinib improves alopecia areata and may help psoriasis but might not be ideal for psoriatic arthritis.
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Etrasimod is safe but not effective for severe alopecia areata, though it may help milder cases.
Oral betamethasone mini-pulses effectively treat moderate to severe alopecia areata with manageable side effects.
April 2025 in “Pakistan Journal of Health Sciences” Weekly Azathioprine Pulse therapy is more effective than Betamethasone Oral Mini-Pulse for hair regrowth in moderate to severe Alopecia Areata.
Tofacitinib significantly regrows hair in severe alopecia without major side effects.
January 2025 in “International Journal of Dermatology Venereology and Leprosy Sciences” Tofacitinib improved hair regrowth and quality of life in children with alopecia areata, with mild side effects.
January 2025 in “Dermatologic Therapy” Baricitinib works better for alopecia areata in patients not previously treated with tofacitinib.
September 2024 in “Journal of Cosmetic Dermatology” Combining CGF and microneedling with betamethasone effectively treats resistant alopecia areata.
Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.
June 2024 in “Australasian Journal of Dermatology” Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.
May 2024 in “JEADV Clinical Practice” A change in SALT scores of 42 or 43 indicates meaningful improvement in alopecia areata treatment.
New treatments for skin conditions show promise, especially Coacillium® for hair growth in young people with alopecia areata.
December 2023 in “Journal of health and rehabilitation research” Oral Apremilast effectively treats alopecia areata in most patients.